Merck & Co.'s top-selling drugs 2024
Published by
Keytruda is not only Merck & Co.’s top product, but also the best-selling drug worldwide, generating some 29.5 billion U.S. dollars in revenue during 2024. The cancer drug with the generic name pembrolizumab increased its revenues by around 4.5 billion U.S. dollars compared to 2023. Another of Merck’s top-ranked pharmaceuticals based on revenue is Januvia, a drug used to treat type 2 diabetes. Oncology and diabetes are two major focus areas of Merck & Co.
Company background
Merck & Co. is a global pharmaceutical company with an interesting historical background. Originally a German company, its operations located in the U.S. were confiscated during World War I and established as a new independent American company. The rest of the company - today known as Merck KGaA – is also still active as a chemical-pharmaceutical company. Today, the American Merck is significantly larger than the German counterpart.
Merck’s top product Keytruda
Over the last years, Keytruda was ranked first among the top cancer drugs worldwide based on revenue. The oncology market was for years dominated by Roche’s top products, Rituxan, Herceptin, and Avastin, as well as Celgene’s (BMS's) Revlimid. As of today, Keytruda is the global top cancer drug and is expected to keep this position for the years to come.
